THE UBIQUITOUS DISTRIBUTION OF ET-1 AND ITS RECEPTORS IMPLICATES ITS INVOLVEMENT IN A WIDE VARIETY OF PHYSIOLOGIC AND PATHOLOGIC PROCESSES IN THE BODY.

ET-Traps Limited  lead indication is to treat diabetes, both type-1 and type-2, a group of metabolic disorders characterized by high blood sugar levels over a prolonged period. Symptoms of high blood sugar include frequent urination, increased thirst and increased hunger. If left untreated, diabetes can cause many complications. Acute complications can include diabetic ketoacidosis, hyperosmolar hyperglycemic state, or death. Serious long-term complications include cardiovascular disease, stroke, chronic kidney disease, foot ulcers, and damage to the eyes.  Currently available therapies are mainly limited to glucose control medications and medications to treat the disease complications and hence, do not prevent progression of disease that is linked to the irreversible damage to the vital organs.

The ET-traps approach to diabetes provides therapeutic synergy for (i) bringing back the pathologically elevated levels of endothelin-1 and (ii) repair of damage caused to the vital organs (long-term complications).

If you or someone you know has been newly diagnosed, please find clear and informative information about the condition here.

Please note, diabetes is more than just high glucose. Click here to find out more. 

We established our PoC in the diabetes disease space. However, elevated/ pathological levels of endothelin-1 are also found in the following diseases:

• atherosclerosis
• cardiac hypertrophy
•  ischemic heart disease
•  heart failure
• stroke

• Alzheimer's disease
• Multiple sclerosis
• Parkinson's disease